US FDA reveals drug center five-year plan
This article was originally published in SRA
The US Food and Drug Administration's Center for Drug Evaluation and Research has outlined details of its strategies for smarter regulation, scientific innovation, lean management and business innovation aimed at strengthening and enhancing the agency's regulatory operations, addressing certain challenges and delivering on its public health mission over the next five years1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.